- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02511873
Fycompa in Subjects With Small Fiber Neuropathy (SFN)
January 26, 2016 updated by: Todd Levine, MD, PNA Center for Neurological Research
Randomized Crossover Trial of Fycompa in the Treatment of Pain Associated With Small Fiber Neuropathy (SFN)
This is a Phase II, 2 arm randomized crossover study.
Subjects will be assigned to either active agent or placebo and then crossover to the other arm.
This study is designed to evaluate whether Fycompa improves the quality of life in patients with small fiber neuropathy.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study will enroll 30 patients from our center alone with a proven SFN diagnosis by a skin biopsy assessment of intraepidermal nerve fiber density.
The patients must also have a pain score of a least 5 on a VAS Scale.
Patients will receive Fycompa 2mg tablets.
Each week patients will be allowed to titrate up by 2mgs up to a maximum dose of 8mg a day.
This dosing has been used in numerous pain studies when no single dose has been proven to be effective.
This does not seem to reduce the validity of the placebo phase.
Patients can choose the dose they feel is best tolerated and most efficacious.
Once patients choose this dose they will be randomized into two arms.
Each arm will last 6 weeks.
Such that patient will receive the dose they chose as most efficacious for 6 weeks or matching placebo for 6 weeks.
Then each patient will crossover to the other arm.
Investigator will assess compliance by counting pills at each visit.
This will provide the ability to see which dose most patients prefer and then study the dose in a blinded randomized fashion.
There will be 5 office visits and 3 phone visits in the study and .
Patients will keep a diary of weekly VAS pain scores.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85018
- PNA Center for Neurological Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Small Fiber Neuropathy(SFN) proven by skin biopsy assessment of intraepidermal nerve fiber density.
- Pain scores of at least a 5 on a VAS scale.
- Male or Female 18 to 60 years old.
- Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
- Stable dose of current pain medication or any medication used for SFN 60 days prior to screening.
- Women of reproductive age must agree to use double-barrier method of contraception.
Exclusion Criteria:
- History of intolerance or hypersensitivity to Fycompa.
- History of psychosis, drug or alcohol abuse within the last 2 years.
- Malignancy within the last 2 years (except skin cancer).
- Clinically significant condition (including but not limited to cardiovascular or hepatic diseases and seizure disorders).
- Pregnant females, breastfeeding females, females of childbearing potential not using effective contraception.
- Subjects with other severe pain conditions which may impair the self-assessment of pain due to SFN.
- Exclusion medications for this study: Carbamazepine, Carbatrol, Tegretol, Tegretol XR, Equetro, Epitol, Phenytoin, Dilantin, Phenytek, Oxcarbazepine, Trileptal, Rifampin, Refadin, Rimactane and St. John Wort.
- Subjects with renal impairment or on hemodialysis or who have hepatic impairment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fycompa
Fycompa dose is chosen based on tolerability and efficacy.
2mg to 8mg daily for 6 weeks then washed out.
|
Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
Other Names:
|
Placebo Comparator: Placebo
Inactive ingredient equal to 2mg tablets
|
Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To Assess the Change of Pain Symptoms Upon Treatment of Fycompa in Comparison to Placebo using Visual Analog Scale (VAS) andBrief Pain inventory(BPI) Short Form
Time Frame: Baseline, Week 5, Week 12 and Week 18
|
Baseline, Week 5, Week 12 and Week 18
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To Assess improvement of Quality of Life Upon Treatment of Fycompa in Comparison to Placebo using Neuro QOL Lower Extremity Function Scale, Patient Global impression of Change (PGIC) Scale and Treatment Satisfaction Questionnaire for Medication (TSQM)
Time Frame: Baseline, Week 5, Week 12 and Week 18
|
Baseline, Week 5, Week 12 and Week 18
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Todd Levine, MD, PNA Center for Neurological Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Anticipated)
December 1, 2016
Study Completion (Anticipated)
December 1, 2016
Study Registration Dates
First Submitted
July 23, 2015
First Submitted That Met QC Criteria
July 27, 2015
First Posted (Estimate)
July 30, 2015
Study Record Updates
Last Update Posted (Estimate)
January 27, 2016
Last Update Submitted That Met QC Criteria
January 26, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FYCOMPA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathy, Small Fiber
-
Henry Ford Health SystemOctapharma USA, Inc.RecruitingSmall Fiber Neuropathy | Autoimmune Small Fiber Neuropathy | Inflammatory Polyneuropathy | Immune-Mediated NeuropathyUnited States
-
University of AlbertaCapital Health, CanadaTerminated
-
Johns Hopkins UniversityPfizerCompletedIdiopathic Small Fiber NeuropathyUnited States
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
JFK Medical CenterUnknownPeripheral NeuropathyUnited States
-
Aalborg University HospitalUniversity of Aarhus; Aalborg UniversityNot yet recruitingType 1 Diabetes | Neuropathy, Diabetic | Small Nerve Fiber Neuropathy
-
National Taiwan University HospitalUnknownChronic Kidney Disease | Small-Fiber NeuropathyTaiwan
-
Academisch Ziekenhuis MaastrichtCompletedSmall Fiber NeuropathyNetherlands
-
Academisch Ziekenhuis MaastrichtTerminated
-
Sorlandet Hospital HFOslo University Hospital; University Hospital of North Norway; University Hospital...Not yet recruitingSmall Fiber Neuropathy | Sensory Neuropathy
Clinical Trials on Fycompa
-
University of FloridaEisai Inc.Recruiting
-
Eisai LimitedCompletedIdiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic SeizuresFrance, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
-
Mayo ClinicCompletedAmyotrophic Lateral SclerosisUnited States
-
Eisai Inc.CompletedPartial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized SeizuresUnited States
-
American University of Beirut Medical CenterTerminatedAmyotrophic Lateral SclerosisLebanon
-
Chinese University of Hong KongUnknownGeneralized Epilepsy | Focal Epilepsy | Partial Seizures, SimpleHong Kong
-
Eisai Inc.Completed
-
Seoul National University HospitalCompletedElectroencephalographyKorea, Republic of
-
Eisai Korea Inc.Recruiting